Development of a live attenuated dengue virus vaccine using reverse genetics

Viral Immunology

Volumn 19, Issue 1, 2006, Pages 10-32

  Blaney Jr , Joseph E ^a   Durbin, Anna P ^b   Murphy, Brian R ^a   Whitehead, Stephen S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; LIVE VACCINE;

3' UNTRANSLATED REGION; AEDES AEGYPTI; ANOREXIA; ARTHRALGIA; DENGUE; DENGUE VIRUS; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DISEASE ACTIVITY; DISEASE SEVERITY; DNA MODIFICATION; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; ENDEMIC DISEASE; EYE PAIN; FEVER; GENE DELETION; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LICENSING; MALAISE; MOSQUITO; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; NUCLEOTIDE SEQUENCE; REVIEW; RHESUS MONKEY; SEROTYPE; SHOCK; SOUTH AMERICA; SOUTHEAST ASIA; VIRUS IMMUNITY;

DENGUE; GENETIC ENGINEERING; HUMANS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL VACCINES;

AEDES AEGYPTI; DENGUE VIRUS; DENGUE VIRUS TYPE 3; MACACA MULATTA;

EID: 33645471457     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2006.19.10     Document Type: Review

References (97)

1. Almond, J., J. Clemens, H. Engers, S. Halstead, H. Khiem, A. Pablos-Mendez, Y. Pervikov, and T. Tram. 2002. Accelerating the development and introduction of a dengue vaccine for poor children, 5-8 December 2001, Ho Chi. Minh City, VietNam. Vaccine 20:3043-3046.
2. Alvarez, D.E., A.L. De Lella Ezcurra, S. Fucito, and A.V. Gamarnik. 2005. Role of RNA structures present at the 3′UTR of dengue virus on translation, RNA synthesis, and viral replication. Virology 339:200-212.
3. Bhamarapravati, N., and S. Yoksan. 1997. Live attenuated tetravalent dengue vaccine, pp. 367-377. In: D.J. Gubler and G. Kuno (eds.). Dengue and Dengue Hemorrhagic fever. CAB International, New York.
4. Blaney, J.E., Jr., C.T. Hanson, C.Y. Firestone, K.A. Hanley, B.R. Murphy, and S.S. Whitehead. 2004. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am. J. Trop. Med. Hygiene 71:811-821.
5. Blaney, J.E., Jr., C.T. Hanson, K.A. Hanley, B.R. Murphy, and S.S. Whitehead. 2004. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. BMC Infect. Dis. 4:39.
6. Blaney, J.E., Jr., D.H. Johnson, C.Y. Firestone, C.T. Hanson, B.R. Murphy, and S.S. Whitehead. 2001. Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice. J. Virol. 75:9731-9740.
7. Blaney, J.E., Jr., D.H. Johnson, G.G. Manipon, C.Y. Firestone, C.T. Hanson, B.R. Murphy, and S.S. Whitehead. 2002. Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology 300:125-139.
8. Blaney, J.E., Jr., G.G. Manipon, B.R. Murphy, and S.S. Whitehead. 2003. Temperature sensitive mutations in the genes encoding the NS1, NS2A, NS3, and NS5 nonstructural proteins of dengue virus type 4 restrict replication in the brains of mice. Arch. Virol. 148:999-1006.
9. Blaney, J.E., Jr., J.M. Matro, B.R. Murphy, and S.S. Whitehead. 2005. Recombinant, live attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J. Virol. 79:5516-5528.
10. Blaney, J.E., G.G. Manipon, C.Y. Firestone, D.H. Johnson, C.T. Hanson, B.R. Murphy, and S.S. Whitehead. 2003. Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. Vaccine 21:4317-4327.
11. Bray, M., and C.J. Lai. 1991. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc. Natl. Acad. Sci. U.S.A. 88:10342-10346.
12. Bray, M., B.T. Zhao, L. Markoff, K.H. Eckels, R.M. Chanock, and C.J. Lai. 1989. Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus encephalitis. J. Virol. 63:2853-2856.
13. Bukowski, J.F., I. Kurane, C.J. Lai, M. Bray, B. Falgout, and F.A. Ennis. 1989.-Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes. J. Virol. 63:5086-5091.
14. Burke, D.S., and T.P. Monath. 2001. Flaviviruses, pp. 1043-1125. In D.M. Knipe and P.M. Howley (eds.). Fields Virology, Fourth Edition, Vol. 1. Lippincott Williams & Wilkins, Philadelphia.
15. Burke, D.S., A. Nisalak, D.E. Johnson, and R.M. Scott. 1988. A prospective study of dengue infections in Bangkok. Am. J. Trop. Med. Hygeine 38:172-180.
16. Couvelard, A., P. Marianneau, C. Bedel, M. T. Drouet, F. Vachon, D. Henin, and V. Deubel. 1999. Report of a fatal case of dengue infection with hepatitis: demonstration of dengue antigens in hepatocytes and liver apoptosis. Hum. Pathol. 30:1106-1110.
17. Crill, W.D., and J.T. Roehrig. 2001. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 75:7769-7773.
18. Durbin, A.P., R.A. Karron, W. Sun, D.W. Vaughn, M.J. Reynolds, J.R. Perreault, B. Thumar, R. Men, C.J. Lai, W.R. Elkins, R.M. Chanock, B.R. Murphy, and S.S. Whitehead. 2001. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am. J. Trop. Med. Hyg. 65:405-413.
19. Durbin, A.P., S.S. Whitehead, J. McArthur, J.R. Perreault, J. Blaney, B. Thumar, B.R. Murphy, and R.A. Karron. 2005. rDEN4Δ30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J. Infect. Dis. 191: 710-718.
20. Eckels, K.H., R.M. Scott, W.H. Bancroft, J. Brown, D.R. Dubois, P.L. Summers, P.K. Russell, and S.B. Halstead. 1984. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells. Am. J. Trop. Med. Hyg. 33:684-689.
21. Edelman, R., C.O. Tacket, S.S. Wasserman, D.W. Vaughn, K.H. Eckels, D.R. Dubois, P.L. Summers, and C.H. Hoke. 1994. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J. Infect. Dis. 170:1448-1455.
22. Edelman, R., S.S. Wasserman, S.A. Bodison, R.J. Putnak, K.H. Eckels, D. Tang, N. Kanesa-Thasan, D.W. Vaughn, B.L. Innis, and W. Sun. 2003. Phase I trial of 16 formulations of a tetravalent live attenuated dengue vaccine. Am. J. Trop. Med. Hyg. 69:48-60.
23. Endy, T.P., A. Nisalak, S. Chunsuttitwat, D.W. Vaughn, S. Green, F.A. Ennis, A.L. Rothman, and D.H. Libraty. 2004. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J. Infect. Dis. 189:990-1000.
24. Gubler, D.J. 1998. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11:480-496.
25. Gubler, D.J. 1998. The global pandemic of dengue/dengue haemorrhagic fever: current status and prospects for the future. Ann. Acad. Med. Singapore 27:227-234.
26. Gubler, D.J., and M. Meltzer. 1999. Impact of dengue/dengue hemorrhagic fever on the developing world. Adv. Virus Res. 53:35-70.
27. Gubler, D.J., D. Reed, L. Rosen, and J.R. Hitchcock, Jr. 1978. Epidemiologic, clinical, and virologic observations on dengue in the Kingdom of Tonga. Am. J. Trop. Med. Hyg. 27:581-589.
28. Gubler, D.J., W. Suharyono, I. Lubis, S. Eram, and S. Gunarso. 1981. Epidemic dengue 3 in central Java, associated with low viremia in man. Am. J. Trop. Med. Hyg. 30:1094-1099.
29. Guirakhoo, F., J. Arroyo, K.V. Pugachev, C. Miller, Z.X. Zhang, R. Weltzin, K. Georgakopoulos, J. Catalan, S. Ocran, K. Soike, M. Ratterree, and T.P. Monath. 2001. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol. 75:7290-7304.
30. Guirakhoo, F., K. Pugachev, J. Arroyo, C. Miller, Z.X. Zhang, R. Weltzin, K. Georgakopoulos, J. Catalan, S. Ocran, K. Draper, and T.P. Monath. 2002. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298:146-159.
31. Guirakhoo, F., K. Pugachev, Z. Zhang, G. Myers, I. Levenbook, K. Draper, J. Lang, S. Ocran, F. Mitchell, M. Parsons, N. Brown, S. Brandler, C. Fournier, B. Barrere, F. Rizvi, A. Travassos, R. Nichols, D. Trent, and T. Monath. 2004. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 78:4761-4775.
32. Guirakhoo, F., Z. Zhang, T.J. Chambers, S. Delagrave, J. Arroyo, A.D. Barrett, and T.P. Monath. 1999. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257: 363-372.
33. Guzman, M.G., and G. Kouri. 2003. Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges. J. Clin. Virol. 27:1-13.
34. Guzman, M.G., G. Kouri, E. Martinez, J. Bravo, R. Riveron, M. Soler, S. Vazquez, and L. Morier. 1987. Clinical and serologic study of Cuban children with dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Bull. Pan. Am. Health Organ. 21:270-279.
35. Guzman, M.G., G. Kouri, L. Valdes, J. Bravo, M. Alvarez, S. Vazques, I. Delgado, and S.B. Halstead. 2000. Epidemiologic studies on dengue in Santiago de Cuba, 1997. Am. J. Epidemiol. 152:793-799; discussion 804.
36. Guzman, M.G., G.P. Kouri, J. Bravo, M. Soler, S. Vazquez, and L. Morier. 1990. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am. J. Trop. Med. Hyg. 42:179-184.
37. Halstead, S.B. 1974. Etiologies of the experimental dengues of Siler and Simmons. Am. J. Trop. Med. Hyg. 23:974-982.
38. Halstead, S.B. 2003. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60:421-467.
39. Halstead, S.B. 1988. Pathogenesis of dengue: challenges to molecular biology. Science 239:476-481.
40. Halstead, S.B., N.T. Lan, T.T. Myint, T.N. Shwe, A. Nisalak, S. Kalyanarooj, S. Nimmannitya, S. Soegijanto, D.W. Vaughn, and T.P. Endy. 2002. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg. Infect. Dis. 8:1474-1479.
41. Halstead, S.B., and N.J. Marchette. 2003. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. Am. J. Trop. Med. Hyg. 69:5-11.
42. Halstead, S.B., S. Nimmannitya, and S.N. Cohen. 1970. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J. Biol. Med. 42:311-328.
43. Hanley, K.A., J.J. Lee, J.E. Blaney, Jr., B.R. Murphy, and S.S. Whitehead. 2002. Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes. J. Virol. 76:525-531.
44. Hanley, K.A., L.R. Manlucu, L.E. Gilmore, J.E. Blaney, Jr., C.T. Hanson, B.R. Murphy, and S.S. Whitehead. 2003. A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4. Virology 312:222-232.
45. Hanley, K.A., L.R. Manlucu, G.G. Manipon, C.T. Hanson, S.S. Whitehead, B.R. Murphy, and J.E. Blaney, Jr. 2004. Introduction of mutations into the non-structural genes or 3′ untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity. Vaccine 22:3440-3448.
46. Huang, C.Y., S. Butrapet, K.R. Tsuchiya, N. Bhamarapravati, D.J. Gubler, and R.M. Kinney. 2003. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J. Virol. 77:11436-11447.
47. Huerre, M.R., N.T. Lan, P. Marianneau, N.B. Hue, H. Khun, N.T. Hung, N.T. Khen, M.T. Drouet, V.T. Huong, D.Q. Ha, Y. Buisson, and V. Deubel. 2001. Liver histopathology and biological correlates in five cases of fatal dengue fever in Vietnamese children. Virchows Arch. 438:107-115.
48. Innis, B.L. 1997. Antibody responses to dengue virus infection, pp. 221-244. In: D.J. Gubler and G. Kuno (eds.). Dengue and Dengue Hemorrhagic Fever. CAB International, New York.
49. Innis, B.L. 1995. Dengue and dengue hemorrhagic fever, pp. 103-146. In: J.S. Porterfield (ed.). Exotic Viral Infections. Chapman and Hall, London.
50. Innis, B.L., K.H. Eckels, E. Kraiselburd, D.R. Dubois, G.F. Meadors, D.J. Gubler, D.S. Burke, and W.H. Bancroft. 1988. Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation. J. Infect. Dis. 158:876-880.
51. Kalayanarooj, S., D.W. Vaughn, S. Nimmannitya, S. Green, S. Suntayakorn, N. Kunentrasai, W. Viramitrachai, S. Ratanachu-eke, S. Kiatpolpoj, B.L. Innis, A. L. Rothman, A. Nisalak, and F.A. Ennis. 1997. Early clinical and laboratory indicators of acute dengue illness. J. Infect. Dis. 176:313-321.
52. Kanesa-Thasan, N., R. Edelman, C.O. Tacket, S.S. Wasserman, D.W. Vaughn, T.S. Coster, G.J. Kim-Ahn, D.R. Dubois, J.R. Putnak, A. King, P.L. Summers, B.L. Innis, K.H. Eckels, and C.H. Hoke, Jr. 2003. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am. J. Trop. Med. Hyg. 69:17-23.
53. Kanesa-thasan, N., W. Sun, G. Kim-Ahn, S. Van Albert, J.R. Putnak, A. King, B. Raengsakulsrach, H. Christ-Schmidt, K. Gilson, J.M. Zahradnik, D.W. Vaughn, B.L. Innis, J.F. Saluzzo, and C.H. Hoke, Jr. 2001. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19:3179-3188.
54. Kaufman, B.M., P.L. Summers, D.R. Dubois, W.H. Cohen, M.K. Gentry, R.L. Timchak, D.S. Burke, and K.H. Eckels. 1989. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 41:576-580.
55. Kaufman, B.M., P.L. Summers, D.R. Dubois, and K.H. Eckels. 1987. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 36:427-434.
56. Kitchener, S., M. Nissen, P. Nasveld, R. Forrat, S. Yoksan, J. Lang, and J.F. Saluzzo. 2006. Immunogenicity and safety of two live attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine (in press).
57. Kliks, S.C., S. Nimmanitya, A. Nisalak, and D.S. Burke. 1988. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 38:411-419.
58. Kliks, S.C., A. Nisalak, W.E. Brandt, L. Wahl, and D.S. Burke. 1989. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40:444-451.
59. Kuhn, R.J., W. Zhang, M.G. Rossmann, S.V. Pletnev, J. Corver, E. Lenches, C.T. Jones, S. Mukhopadhyay, P.R. Chipman, E.G. Strauss, T.S. Baker, and J.H. Strauss. 2002. Structure of dengue virus. Implications for flavivirus organization, maturation, and fusion. Cell 108:717-725.
60. Kuo, C.H., D.I. Tai, C.S. Chang-Chien, C.K. Lan, S.S. Chiou, and Y.F. Liaw. 1992. Liver biochemical tests and dengue fever. Am. J. Trop. Med. Hyg. 47:265-270.
61. Kurane, I., and F.A. Ennis. 1997. Immunopathogenesis of dengue virus infections, pp. 273-290. In: D.J. Gubler and G. Kuno (eds.). Dengue and Dengue Hemorrhagic Fever. CAB International, New York.
62. Kurane, I., A. Meager, and F.A. Ennis. 1989. Dengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon gamma production, and cytotoxic activity. J. Exp. Med. 170:763-775.
63. Lai, C.J., B.T. Zhao, H. Hori, and M. Bray. 1991. Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. Proc. Natl. Acad. Sci. U.S.A. 88:5139-143.
64. Lanciotti, R.S., D.J. Gubler, and D.W. Trent. 1997. Molecular evolution and phylogeny of dengue-4 viruses. J. Gen. Virol. 78:2279-2284.
65. Lanciotti, R.S., J.G. Lewis, D.J. Gubler, and D.W. Trent. 1994. Molecular evolution and epidemiology of dengue-3 viruses. J. Gen. Virol. 75:65-75.
66. Men, R., M. Bray, D. Clark, R.M. Chanock, and C.J. Lai. 1996. Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J. Virol. 70:3930-3937.
67. Mohan, B., A.K. Patwari, and V.K. Anand. 2000. Hepatic dysfunction in childhood dengue infection. J. Trop. Pediatr. 46:40-43.
68. Monath, T.P. 1999. Yellow fever, pp. 815-879. In: S.A. Plotkin and W. A. Orenstein (eds.). Vaccines, Third Edition W.B. Saunders, Philadelphia.
69. Monath, T.P., N. Kanesa-Thasan, F. Guirakhoo, K. Pugachev, J. Almond, J. Lang, M.J. Quentin-Millet, A.D. Barrett, M.A. Brinton, M.S. Cetron, R.S. Barwick, T.J. Chambers, S.B. Halstead, J.T. Roehrig, R.M. Kinney, R. Rico-Hesse, and J.H. Strauss. 2005. Recombination and flavivirus vaccines: a commentary. Vaccine 23:2956-2958.
70. Montagnon, B., and J. Vincent-Falquet. 1998. Experience with the Vero cell line, pp. 119-123. In: F. Brown, E. Griffths, F. Horaud, and J. Petricciani (eds.). Safety of Biological Products Prepared from Mammalian Cell Culture, Vol. 93. Karger, Basel.
71. Morens, D.M., and S.B. Halstead. 1990. Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies. J. Gen. Virol. 71:2909-2914.
72. Mota, J., M. Acosta, R. Argotte, R. Figueroa, A. Mendez, and C. Ramos. 2005. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 23:3469-3476.
73. Murgue, B., C. Roche, E. Chungue, and X. Deparis. 2000. Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia. J. Med. Virol. 60:432-438.
74. Murphy, B.R., J.E. Blaney, Jr., and S.S. Whitehead. 2004. Arguments for live flavivirus vaccines. Lancet 364:499-500.
75. Murphy, B.R., and R.M. Chanock. 2001. Immunization against viral diseases, pp. 435-468. In: D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman, and S.E. Strauss (eds.). Fields Virology, Vol. 1. Lippincott Williams & Wilkins, Philadelphia.
76. Nguyen, T.H., H.Y. Lei, T.L. Nguyen, Y.S. Lin, K.J. Huang, B.L. Le, C.F. Lin, T.M. Yeh, Q.H. Do, T.Q. Vu, L.C. Chen, J.H. Huang, T.M. Lam, C.C. Liu, and S.B. Halstead. 2004. Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J. Infect. Dis. 189:221-232.
77. Patriarca, P.A., P.F. Wright, and T.J. John. 1991. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev. Infect. Dis. 13: 926-939.
78. Pletnev, A.G., M. Bray, and C.J. Lai. 1993. Chimeric tickborne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice. J. Virol. 67: 4956-4963.
79. Pletnev, A.G., R. Putnak, J. Speicher, E.J. Wagar, and D.W. Vaughn. 2002. West Nile virus / dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective ef-ficacy. Proc. Natl. Acad. Sci. U.S.A. 99:3036-3041.
80. Proutski, V., E.A. Gould, and E.C. Holmes. 1997. Secondary structure of the 3′ untranslated region of flaviviruses: similarities and differences. Nucleic Acids Res. 25:1194-1202.
81. Rice, C.M. 1996. Flaviviridae: the viruses and their replication, pp. 931-959. In: B.N. Fields, D.M. Knipe, P.M. Howley, R.M. Chanock, J.L. Melnick, T.P. Monath, B. Roizman, and S.E. Straus (eds.). Fields Virology, Third Edition. Lippincott-Raven, Philadelphia.
82. Rice, C.M., A. Grakoui, R. Galler, and T.J. Chambers. 1989. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biol. 1:285-296.
83. Rico-Hesse, R. 2003. Microevolution and virulence of dengue viruses. Adv. Virus Res. 59:315-341.
84. Roehrig, J.T. 1997. Immunochemistry of dengue viruses, pp. 199-220. In: D.J. Gubler and G. Kuno (eds.). Dengue and Dengue Hemorrhagic Fever. CAB International, New York.
85. Roehrig, J.T., R.A. Bolin, and R.G. Kelly. 1998. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica [In process citation]. Virology 246:317-328.
86. Russell, P.K., A. Nisalak, P. Sukhavachana, and S. Vivona. 1967. A plaque reduction test for dengue virus neutralizing antibodies. J. Immunol. 99:285-290.
87. Sabchareon, A., J. Lang, P. Chanthavanich, S. Yoksan, R. Forrat, P. Attanath, C. Sirivichayakul, K. Pengsaa, C. Pojjaroen-Anant, L. Chambonneau, J.F. Saluzzo, and N. Bhamarapravati. 2004. Safety and immunogenicity of a three dose regimen of two tetravalent live attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr. Infect. Dis. J. 23:99-109.
88. Sabchareon, A., J. Lang, P. Chanthavanich, S. Yoksan, R. Forrat, P. Attanath, C. Sirivichayakul, K. Pengsaa, C. Pojjaroen-Anant, W. Chokejindachai, A. Jagsudee, J. F. Saluzzo, and N. Bhamarapravati. 2002. Safety and immunogenicity of tetravalent live attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am. J. Trop. Med. Hyg. 66:264-272.
89. Sabin, A.B. 1952. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1:30-50.
90. Sun, W., R. Edelman, N. Kanesa-thasan, K.H. Eckels, J.R. Putnak, A.D. King, H.-S. Houng, D. Tang, J.M. Scherer, C.H. Hoke, and B.L. Innis. 2003. Vaccination of human volunteers with monovalent and tetravalent live attenuated dengue vaccine candidates. Am. J. Trop. Med. Hyg. 69:24-31.
91. Troyer, J.M., K.A. Hanley, S.S. Whitehead, D. Strickman, R.A. Karron, A.P. Durbin, and B.R. Murphy. 2001. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes - and lack of transmission from vaccinees to mosquitoes. Am. J. Trop. Med. Hyg. 65:414-419.
92. Vaughn, D.W., S. Green, S. Kalayanarooj, B.L. Innis, S. Nimmannitya, S. Suntayakorn, T.P. Endy, B. Raengsakulrach, A.L. Rothman, F.A. Ennis, and A. Nisalak. 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181:2-9.
93. Vaughn, D.W., C.H. Hoke, Jr., S. Yoksan, R. LaChance, B.L. Innis, R.M. Rice, and N. Bhamarapravati. 1996. Testing of a dengue 2 live attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine 14:329-336.
94. Wahid, S.F., S. Sanusi, M.M. Zawawi, and R.A. Ali. 2000. A comparison of the pattern of liver involvement in dengue hemorrhagic fever with classic dengue fever. Southeast Asian J. Trop. Med. Public Health 31:259-263.
95. Whitehead, S.S., B. Falgout, K.A. Hanley, J.E. Blaney Jr., L. Markoff, and B.R. Murphy. 2003. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys. J. Virol. 77:1653-1657.
96. Whitehead, S.S., K.A. Hanley, J.E. Blaney, L.E. Gilmore, W.R. Elkins, and B.R. Murphy. 2003. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 21:4307-4316.
97. World Health Organization. 1997. Dengue Haemorrhagic Fever: Diagnosis, Treatment Prevention and Control, Second Edition. World Health Organization, Geneva.